Exelixis / Swedish Orphan Biovitrum AB / PricewaterhouseCoopers AB / Sobi / Biogen Idec / Financial Review / Auxilium Pharmaceuticals Inc. / Pfizer / ReFacto Manufacturing / Amgen Sobi / Hyperion Therapeutics Inc. / /
Continent
North America / Europe / /
Country
Sweden / United States / /
Currency
SEK / /
Event
FDA Phase / Business Partnership / Employment Change / M&A / /
IndustryTerm
treatment for advanced head and neck cancer / treatment of Urea Cycle Disorders / treatment of Peyronie's disease / Manufacturing revenue / manufacturing process / treatment of rare disease / drug manufacturing / manufacturing / /
MedicalCondition
Urea Cycle Disorders / Haemophilia / head and neck cancer / Cryopyrin-Associated Periodic Syndromes / chronic treatment / severe oral mucositis / Peyronie's disease / neonatal-onset multisystem inflammatory disease / Dupuytren's contracture / Inflammation / /
Organization
Committee for Medicinal Products for Human Use / European Medicines Agency / US Food and Drug Administration / European Union / /
Person
Geoffrey McDonough / Mikael Winkvist / Dennis Schmidt Pedersen / Further / /
Position
SOBI CEO / candidate / rFVIIIFc / Public Accountant / Auditor / Contents CEO / Senior Vice President Human Resources / CEO / Senior Vice President Human Resources 4 BUSINESS / Director Human Resources / advanced head / CEO and President / Independent Auditor / /
Q3 Pioneer in Rare Diseases Report for the Third Quarter 2013 SOBI |CEO STATEMENT 1